Results 141 to 150 of about 17,802 (177)

Oral HPV-Related Epithelial Proliferation during Fingolimod Therapy: First Case Report and Review of the Literature. [PDF]

Head Neck Pathol
Tikkhanarak K, Saepoo J, Handoo N, Lanzel E, Timmons S, Frost R, Hellstein J.   +6 more
europepmc   +1 more source

Fingolimod Acutely Facilitates the Activation of TRKB in a BDNF-dependent Manner. [PDF]

Cell Mol Neurobiol
Brunello CA, Muñoz PP, Araujo JP, Seiffert N, Kaurinkoski K, Casarotto P, Biojone C, Castrén E.   +7 more
europepmc   +1 more source

Clinical and radiological outcomes of directed treatment transitions from Gilenya^® to generic fingolimod. [PDF]

Mult Scler
Patel MA, Punnen TG, Shan KS, McCreary MC, Wright CM, Munoz SB, Hardeman P, Burgess KW, Greenberg BM, Horton LA, Sguigna PV, Tardo LM, Stüve O, Okuda DT.   +13 more
europepmc   +1 more source

Peroxiredoxin 6 Alone or in Combination with Fingolimod Ameliorates EAE. [PDF]

Curr Neuropharmacol
Lunin SM, Novoselova EG, Glushkova OV, Parfenyuk SB, Kuzekova AA, Novoselova TV, Sharapov MG, Mubarakshina EK, Goncharov RG, Khrenov MO.   +9 more
europepmc   +1 more source

Treatment Effects on Chronic Active Lesions in Multiple Sclerosis: Current Evidence and Future Perspectives. [PDF]

Neurol Ther
Preziosa P, Guido G, Filippi M, Rocca MA.   +3 more
europepmc   +1 more source

Tenofovir in Progressive Multifocal Leukoencephalopathy: Virus Suppression Without Clinical Benefit in 2 Cases. [PDF]

Neurol Neuroimmunol Neuroinflamm
Lier J, Mrestani A, Braune M, Hönemann M, Pelz JO, Rumpf JJ, Then Bergh F.   +6 more
europepmc   +1 more source

Effects of Selective Sphingosine-1-Phosphate Receptor 1 Agonist, TRV045, on Evoked Pain Tests: An Exploratory, Four-Way Cross-Over Study in Healthy Volunteers. [PDF]

Eur J Pain
Bakker WA, Eijsvogel P, Klaassen ES, Kim J, Chen R, Demitrack MA, Dahan A, Niesters M, Hijma HJ, Groeneveld GJ.   +9 more
europepmc   +1 more source

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges. [PDF]

Neurol Ther
Chan A, Alroughani R, Calabrese M, Havrdová EK, Obeidat AZ, Schmierer K, Andersson M, Bek L, Savarin C, Korich J, Bonsignore L, de Seze J.   +11 more
europepmc   +1 more source

Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other Oral Treatments Among Patients with Multiple Sclerosis. [PDF]

Neurol Ther
Gupta AS, MacEwan JP, Anderson J, Zhao X, Kim S, Surinach A, Hong Y, Phillips AL, Chen X.   +8 more
europepmc   +1 more source

Early switching to ofatumumab avoids a rebound effect after natalizumab cessation in multiple sclerosis patients. [PDF]

Mult Scler J Exp Transl Clin
De Seze J, Bernard E, Betsch C, Nivoix Y, Bigaut K, Kremer L, Collongues N, Lanotte L, Ouallet JC.   +8 more
europepmc   +1 more source